Last reviewed · How we verify
NCT04648852: HUNT4HF
The HUNT for Heart Failure" Risk Score
trial testing Heart failure risk estimation in Heart Failure in 36,511 participants. Completed in 30 June 2023.
30 June 2023
Quick facts
| Lead sponsor | Helse Nord-Trøndelag HF |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 36,511 |
| Start date | 1 October 2017 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Heart failure risk estimation
Conditions studied
- Heart Failure — all drugs for Heart Failure →
Sponsor
Helse Nord-Trøndelag HF — full company profile →
Who can join
Adults 18 to 99, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this population study aim is to evaluate risk factors for heart failure and combine these into a new heart failure risk score. Secondly, the heart failure risk score will be internally and externally validated, and compared with established heart failure risk scores. Additionally, the prevalence of heart failure as well as the distribution of the heart failure risk score in the general population will be evaluated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score.
Ofstad AP, Brunborg C, Johansen OE, Mørkedal B, et al · · 2023 · cited 4× · PMID 37248650 · DOI 10.1002/ehf2.14390
Verify or expand the search:
- PubMed search for NCT04648852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Helse Nord-Trøndelag HF trials
Trials by the same sponsor.
- NCT04857671 — Botulinum Toxin A in Frequent and Chronic Tension-type Headache · Phase 3 · completed
- NCT05049135 — Feasibility of a Sensor-less Sleep Monitor (Somnofy®) in Diagnosis and Follow-up in Obstructive Sleep Apnea. · completed
- NCT05011682 — The Effect of 'Medical Nutrition Therapy' on Post-bariatric Hypoglycemia 2-4 Years After Gastric Bypass Surgery · NA · completed
- NCT04580095 — Artificial Intelligence for Improved Echocardiography · NA · completed
- NCT04292457 — Namsos Anaesthesia Children Outcome Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04648852 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helse Nord-Trøndelag HF
- Last refreshed: 15 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04648852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing